Online inquiry

IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2527MR)

This product GTTS-WQ2527MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CALCRL gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001271751.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10203
UniProt ID Q16602
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ2527MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2238MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA aVWF81
GTTS-WQ13409MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ7670MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ5373MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ14942MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ295MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ253MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ11135MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MDX-1103
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW